Search Results
376 items found for "Helen Su"
- Neurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study Evaluating Valbenazine...
Placebo-Adjusted Mean Reduction in TMC Score of 3.2 Units in Valbenazine-Treated Patients- Company Plans to Submit Supplemental New Drug Application to U.S.
- InterAx Biotech AG and Boehringer Ingelheim take collaborate to unlock orphan targets leveraging ...
. 💊 InterAx Biotech AG discovery platform was already successfully applied in projects with biopharmaceutical
- Naggie and Rajagopal Elected Members of American Society for Clinical Investigation
March 2022 "March 3, 2022 Susanna Naggie, MD, and Sudarshan Rajagopal, MD, PhD Two School of Medicine faculty members — Susanna Naggie, MD , and Sudarshan Rajagopal, MD, PhD — have been elected to the
- Inversago Pharma Completes Phase 1 Clinical Trial on First-in-Class, Peripheral CB1 Blocker and...
Company has completed the Phase 1 Clinical Trial for its INV-202 molecule Encouraging Phase 1 results and supportive (“Inversago”), the peripheral CB1 blockade company, announced today the successful completion of the
- Therapeutic validation of an orphan G protein-coupled receptor: The case of GPR84
August 2022 "Despite the importance of members of the GPCR superfamily as targets of a broad range of
- Murine bone marrow macrophages and human monocytes do not express atypical chemokine receptor 1
publication purporting ACKR1 expression in mouse BM by macrophages, but not erythroblasts and ECs, suggesting
- Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in...
KarXT also demonstrated an early and sustained statistically significant reduction of symptoms, as assessed
- Anatomy of a partnership: Cancer Research UK teams up with Sosei Heptares
Much of that funding is distributed to support third party research, but the group also does its own
- Effects of Small Molecule Ligands on ACKR3 Receptors
In support of this conclusion, we have shown that ACKR3 is unable to signal through any of the known
- A new Kunitz-type snake toxin family associated with an original mode of interaction with the...
MQs form a new subgroup in the Kunitz family, close to the V2R non-active dendrotoxins and to two V2R-active
- Sosei Heptares recently hosted their annual Scientific Advisory Board (SAB)
"We recently hosted our annual Scientific Advisory Board (SAB) summit at our site within Granta Park.
- GPCR Therapeutics welcomes Dr. Ed Brennan as their new Vice President, Head of Clinical Development
filed more than 10 Investigational New Drug Applications (IND), as well as multiple New Drug (NDA) and Supplemental He went on to study medicine at the Royal College of Surgeons in Ireland before receiving his Medical
- Crinetics Presents Clinical And Research Results At ENDO 2022
CRN04894 reduced both serum cortisol levels and 24-hour urine free cortisol excretion in the presence of sustained
- Neurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital ...
Treatment of Adolescent Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2022 "06/13/22 - Substantial congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD), which demonstrated substantial
- Accelerating GPCR Drug Discovery With Conformation-Stabilizing VHHs
, only a small portion (∼110) of the human GPCRome (consisting of approximately 850 GPCRs) has been successfully
- Inversago Pharma appoints Glenn S. Vraniak as Chief Financial Officer
Officer of Evaxion Biotech A/S, an AI enabled immuno-oncology company and led the company through a successful IPO on Nasdaq in February 2021, and successfully raised follow-on capital later that same year. Officer of electroCore, Inc. and was a key member of the management team that led the company through a successful
- Targeting the M1 muscarinic receptor in neurodegenerative disease
April 2022 "By Sophie Bradley | Apr 12, 2022 Summary Sophie Bradley, Translational Sciences Associate Director at Sosei Heptares , recently presented at the Keystone Symposia GPCR Conference, a summary
- GPCR Therapeutics Expands Scientific Advisory Board
Jon Wigginton will provide scientific expertise to support the company’s research and clinical development GPCR just had a very successful first meeting including all the Scientific Advisory Board."
- Modulation of Striatal Adenosinergic Function by HTL0041178, a Selective GPR52 Agonist
This work highlights an important interplay between the adenosinergic and dopaminergic systems and suggests
- Addex Therapeutics Completes Patient Enrollment For Dipraglurant Blepharospasm Phase 2 Clinical ...
Dipraglurant selectively targets the metabotropic glutamate receptor subtype 5 (mGlu5) through allosteric
- Crinetics Pharmaceuticals Announces Pricing Of Underwritten Common Stock Offering
The offering is expected to close on or about April 18, 2022, subject to the satisfaction of customary
- Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B ...
Topline results from 40 subjects are expected in the second half of the calendar year."
- Dr. Juan José Fung - Dr. GPCR Podcast
Subscribe today! https://buff.ly/32fzGbO #gpcr #drgpcr #podcast
- Dr. Marta Filizola - Dr. GPCR Podcast
Subscribe to the podcast today and get notified when new episodes are released!
- Dr. Josephine (Pina) Cardarelli - Dr. GPCR Podcast
Subscribe to the podcast today and get notified when new episodes are released!
- AELIS PHARMA launches their IPO for €25 million
February 2022 "We are proud to announce the success of our IPO!
- Integration and Spatial Organization of Signaling by G Protein-Coupled Receptor Homo- and ...
Here, we summarize evidence that supports these conjectures, fostering new ideas about the physiological
- A role for BET proteins in regulating basal, dopamine-induced and cAMP/PKA-dependent ...
Here, we demonstrate that in adult rats, inhibition of BET proteins with the bromodomain inhibitor JQ1 suppressed the expression of ~25% of D1R-upregulated genes, while also increasing the expression of a subset of